The market size of non blood tumor drugs will reach 140.8 billion US dollars

Source: Ding Xiangyuan 2016-04-15 according to GBI research, a business intelligence provider, the global market size of non blood tumor treatment drugs will increase from $72.9 billion in 2014 to $140.8 billion in 2021, nearly doubling The company's latest report points out that although many commercially successful products, including Avastin, ibital and Herceptin, have expired or are about to expire their patents, there will still be strong growth in non blood tumor drugs Avastin's patents will first expire in the EU in 2018, while the other two drugs have expired in the EU in 2014 "These drugs are monoclonal antibodies, so they are predicted that their market share and price are not likely to be affected by the expiration of patents, because of the practical problems and regulatory barriers faced by similar biological drugs," explained Bradbury, assistant analyst at GBI research In this regard, the expiration of patents on these drugs will not pose a major obstacle to their market growth ? market drivers will include the increasing global prevalence of cancer and the availability of more targeted treatment drugs that will improve the overall survival of underprivileged patients and enable more cycles of chemotherapy 2954 products are under active research and development According to GBI research, 2954 non blood tumor products are under active research and development, 171 of which are in the phase 3 development or pre registration stage "In terms of competitiveness, although there is no product on the R & D line in the later stage that is expected to reach the success level of the best-selling drugs in the current market, there are still many candidate drugs that are expected to achieve strong sales capacity in the forecast period," Bradbury explained This includes azd-4736 and neratinib, both of which are expected to be blockbuster by 2021 ? some companies are actively involved in the development or sale of these new tumor products, including most of the top 20 pharmaceutical companies, smaller listed companies and private enterprises In particular, Bristol Myers, Johnson & Johnson, Pfizer and Novartis are expected to maintain their strong market share throughout the forecast period In the field of non blood tumor, although Roche's market share is expected to decrease, which is largely due to the expiration of Avastin and erlotinib patents, Roche is still expected to maintain the highest market share of non blood tumor treatment drugs throughout the forecast period.